Purple Biotech (PPBT) has released an update.
Purple Biotech Ltd., a clinical-stage biotech firm, is preparing to showcase interim data from its Phase 2 CM24 pancreatic cancer study at ASCO 2024, indicating a potential reduction in disease progression and death. The company reported decreased operating and net losses in Q1 2024 compared to the previous year, with a strong cash position extending into Q1 2025. Additionally, Purple Biotech is advancing its NT219 trial for head and neck cancer and progressing with its tri-specific antibody platform, with the lead asset expected to enter Phase 1 by early 2026.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
